Absci receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Absci Corp (ABSI)
Track the Absci share price today and view real-time ABSI share price data, including charts, technicals, and key financials. View the ABSI premarket stock price ahead of the market session or assess the after hours quote. Explore ABSI stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Absci Stock Price Today?
The Absci stock price today is 5.665.
What Is the Stock Symbol for Absci?
The stock symbol for Absci is ""ABSI.""
What Stock Exchange Does Absci Trade On?
Absci is listed and trades on the NASDAQ stock exchange.
Is Absci a Good Stock to Buy?
Determining whether Absci or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABSI quote. (ISIN: US00091E1091)
What Is the Absci Stock Price Today?
The Absci stock price today is 5.665.
What Is the Stock Symbol for Absci?
The stock symbol for Absci is ""ABSI.""
What Stock Exchange Does Absci Trade On?
Absci is listed and trades on the NASDAQ stock exchange.
Is Absci a Good Stock to Buy?
Determining whether Absci or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABSI quote. (ISIN: US00091E1091)
5.665
-0.085(-1.48%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.750
5.780
52 wk Range
2.240
6.235
ABSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.7505.780
52 wk Range
2.2406.235
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABSI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.029
Upside
+41.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.029
(+41.72% Upside)
Absci Corp Earnings Call Summary for Q1/2026
- Q1 2026 revenue of $200K missed forecast of $1.43M by 85%; EPS of -$0.19 slightly beat expectations; stock fell 3.11% after-hours to $5.89
- R&D expenses rose 17.7% YoY to $19.3M as company prioritizes ABS-201 development; SG&A costs declined 4.2% to $9.1M
- Cash reserves of $125.7M provide runway into H1 2028, down from $144.3M at end of 2025
- CEO McClain emphasized strategic R&D investment and AI-driven cost optimization; guidance shows negative EPS through 2027 with modest revenue growth
- Analyst price targets range $4.20-$10; company pursuing strategic partnerships and non-dilutive funding amid regulatory and competitive challenges
Last Updated: 08/05/2026, 11:14 am
Read Full TranscriptEarnings
Latest Release
07/05/2026
EPS / Forecast
-0.19 / -0.19
Revenue / Forecast
215K / 1.43M
Compare ABSI to Peers and Sector
Metrics to compare | ABSI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABSIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.6x | −3.1x | −0.6x | |
PEG Ratio | −0.82 | −0.09 | 0.00 | |
Price/Book | 4.6x | 2.4x | 2.6x | |
Price / LTM Sales | 310.9x | 33.0x | 3.2x | |
Upside (Analyst Target) | 48.9% | 95.1% | 48.1% | |
Fair Value Upside | Unlock | 8.9% | 5.8% | Unlock |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Absci (ABSI) Stock Price Today?
The Absci stock price today is 5.665 USD.
What Stock Exchange Does Absci Trade On?
Absci is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Absci?
The stock symbol for Absci is "ABSI."
What Is the Absci Market Cap?
As of today, Absci market cap is 889.160M USD.
What Is Absci's Earnings Per Share (TTM)?
The Absci EPS (TTM) is -0.842.
When Is the Next Absci Earnings Date?
Absci will release its next earnings report on 18/08/2026.
From a Technical Analysis Perspective, Is ABSI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Absci Stock Split?
Absci has split 0 times.
How Many Employees Does Absci Have?
Absci has 140 employees.
What is the current trading status of Absci (ABSI)?
As of 08/05/2026, Absci (ABSI) is trading at a price of 5.665 USD, with a previous close of 5.750 USD. The stock has fluctuated within a day range of 4.750 USD to 5.780 USD, while its 52-week range spans from 2.240 USD to 6.235 USD.
What Is Absci (ABSI) Price Target According to Analysts?
The average 12-month price target for Absci is 8.029 USD, with a high estimate of 10 USD and a low estimate of 4.2 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +41.72% Upside potential.
What Is the ABSI Premarket Price?
ABSI's last pre-market stock price is 5.020 USD. The pre-market share volume is 451,070.000, and the stock has decreased by -0.730, or -12.700%.
What Is the ABSI After Hours Price?
ABSI's last after hours stock price is 4.860 USD, the stock has decreased by -0.890, or -15.480%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.